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doi:10.1016/j.ejvs.2008.02.013Abstract Objective: The aim of this study was to evaluate the early and mid term outcome of
patients with aortic graft infection who underwent in-situ revascularisation with a silver coated
prosthesis.
Material: FromJanuary 2000 toDecember2006, 24 consecutivepatients (22male, 2 female)with
mean age 67 years were prospectively entered in this study of aortic graft infection at our single
centre. Infection was managed with either total (nZ 19) or partial (nZ 5) excision of the
infected graft and in- situ reconstructionwith a silver coated prosthesis, Inter Gard Silver (IGSG).
Methods: The primary endpoint was recurrence of infection. Secondary endpoints were early
and late mortality, peri-operative morbidity, primary graft patency, major amputation rates
and patient survival.
Results: Fourteen patients had a primary graft infection, however 10 of 24 patients had graft
infection secondary to aorto digestive (nZ 9) or aorto urinary (nZ 1) tract fistulas. Bacteriolog-
ical cultures were negative in 8 (33%) patients. Most organisms cultivated where virulent and the
majority of graft infections were polymicrobial (71%). Silver grafts were placed emergently in 6
(25%) patients. Mean follow up 32.5 31.0 months (range 2e78 months).
Peri-operative morbidity and mortality were 46% and 21% respectively. Early interventions
occurred in 6 (25%) patients and late secondary intervention were required in 3 (15.7%), caused
by silver graft reinfection. The late mortality was 26%.
Conclusion: In-situ reconstructionwith thesilvergraft confirmssimilaritywithothermodalities.The
greatest advantage for the silver graft is its ease of use but the risk of reinfection remains significant.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved., Department of Vascular Surgery, Hoˆpital Saint-Roch, 5 rue Pierre Devoluy, BP 319, 06006 Nice Cedex
33492032943.
fr (M. Batt).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Treatment of Aortic Graft Infection with Silver Coated Grafts 183Introduction therapy, particularly vancomycin, was administeredAortic graft infection is a life-threatening complication that
occurs in 1% to 2% of patients who undergo conventional
aortic surgery.1,2 Extra-anatomic bypass (EAB) has long
been the gold standard for such patients.3 However, owing
to the drawbacks of EAB,4e7 in-situ revascularization after
excision of the infected prosthesis has been proposed for
patients with aortic graft infection. Controversy continues
concerning the optimal substitute material to be used after
aortic graft removal. Various substitute materials such as
autogenous veins, cryopreserved arterial allograft, rifampi-
cin bonded prostheses and silver-coated prostheses have all
been tested.4e10 In our initial experience, 11 patients with
an aortic graft infection plus an additional 16 patients from
a multicentre study10 were managed with a silver-coated
prosthesis (Inter Gard Silver prosthesis (IGSG); InterVascu-
lar, La Ciotat, France). Our early promising results with
silver-coated grafts led us to adopt them for routine use
in all of our patients presenting with aortic graft infection.
The bacteriostatic properties of silver salts are well-
recognised, and their efficacy as an antimicrobial agent
when incorporated with medical devices has been reported
extensively.11e16 The IGSG is a woven or knitted polyester
graft coated with type I bovine collagen and silver acetate.
Approved for use in Europe in 1999, the IGSG was the first
antimicrobial prosthesis to obtain the CE mark enabling
the product to be sold in the European Union. However,
despite increasing use of the IGSG, little data is available
concerning the efficacy of the silver ions on the graft over
time or the long-term results of silver-coated prosthetic
grafts in patients with an aortic graft infection. The reasons
for this lack of information include rarity of such infections,
the inability to randomise treatment because of surgical
preference or patient condition and lack of availability of
all grafts especially in emergency situations.
The purpose of this study, conducted at a single univer-
sity hospital, was to analyse the outcome of patients with
an aortic graft infection who underwent in-situ revascular-
isation with a silver-coated prosthesis in order to increase
our knowledge concerning the true utility of this type of
prosthesis.
Material and Methods
All patients (nZ 24) admitted to our hospital for an aortic
graft infection between January 1, 2000 and December 31,
2006 were enrolled in this prospective study following
approval of the local Ethics Committee. During the study
period, the diagnosis of aortic graft infection was based
on clinical examination and CT findings. Preoperative con-
ventional angiography was performed only when clinically
appropriate. Patients with aortic graft infection due to an
aorto-digestive or aorto-urinary tract fistula were classified
as having secondary aortic graft infection. All other
patients were classed as having a primary graft infection
(PGI). Whenever possible, specimens for microbiological
culture, including specimens of any external discharges,
were obtained prior to surgery. Appropriate antibiotic ther-
apy was then initiated in these patients prior to surgery. If
no specimens were obtained, broad spectrum antibioticperi-operatively.
Our surgical policy for treatment of patients with aortic
graft infection was standardised on January 1, 2000. Since
then, our standard procedure comprises excision of the
infected graft and in-situ replacement (ISR) with an IGSG.
Total graft excision was the rule when infection involved
the entire prosthesis. Partial graft excision was performed
only when infection was limited to the graft body or to
a single limb provided that the remainder of the graft was
well encapsulated. During surgery, additional specimens
were taken for bacteriological analysis and all excised
prosthetic grafts were sent for culture. All patients
underwent complete debridement of surrounding tissues
followed by irrigation of the operative fields with liberal
amounts of standard povidone-iodine solution followed by
in-situ reconstruction with the IGSG.
The prosthetic graft was covered with an omental flap
whenever possible. None of the IGSG used in this study was
pre-soaked with rifampicin. We have defined the early, mid
and late post operative periods as <30 days, <12 months
and >12 months respectively.
Following surgery, all patients received peri-procedural
intravenous antibiotics. Oral antibiotics were continued for
3e6 months, depending on the virulence of the specific
organisms cultured. The virulent organisms cultured
included gram-negative, anaerobic, methicillin-resistant
Staphylococcus, fungal, and polymicrobial species, includ-
ing coagulase-negative Staphylococcus.
Serial CT scans of the in-situ graft were obtained before
discharge from the hospital and then at 3 and 6 months post
surgery, and thereafter bi-annually. We have follow-up
data for all our patients up to December 2006.
The primary endpoint was recurrence of infection.
Secondary endpoints were early and late mortality, peri-
operative morbidity, primary graft patency, major
amputation rates and patient survival.
Univariate analysis was performed for prognostic factors
associated with a poor outcome. Pearson’s chi-square or
Fisher’s exact test were used for analysis of categorical
variables. A value of p< 0.05 was considered statistically
significant. The Kaplan-Meier method was used to analyse
patient survival and freedom from reinfection.Results
Twenty-four consecutive patients were admitted to our
department during the study period for aortic graft
infection and were enrolled in the trial. Mean standard
deviation (SD) follow-up was 32.5 31.0 months with
a range between 2 and 78 months. The mean SD age of
these 22 (92%) males and 2 females was 67 9 years ranging
between 44 and 87 years. Present or past cigarette smokers
accounted for 87% of patients in the study with a mean SD
of 53þ 27 pack-years. Other pertinent risk factors included
hypertension (54%), coronary artery disease (50%), chronic
obstructive pulmonary disease (25%), hyperlipidemia
(21%), renal failure defined as creatinin concentra-
tion> 3.0 mg/dl (8%), risk factors for infection (21%),
diabetes mellitus (17%), malnutrition (8%), and immuno
compromised state (8%).
Table 2 CT findings
CT finding N (%)
Perigraft fluid 7 (29)
Perigraft fluid with an air/fluid interface 7 (29)
Retroperiotoneal abscess 10 (42)
Ureterohydronephrosis 4 (17)
Proximal anastomotic false aneurysm 5 (21)
Distal anastomotic pseudoaneurysm 3 ( 8)
Table 3 Summary of the 7 graft duodenal fistula
Characteristics of the 7 patients N (%)
184 M. Batt et al.Initial graft placement was prompted by occlusive
disease in 14 patients (58%) and aneurismal disease in 10
patients (42%). The mean SD interval between initial
prosthetic graft insertion and diagnosis of graft infection
was 73 64 months, ranging between 1 and 264 months.
The bypass configuration of these infected grafts was
aorto-femoral, aorto-aortic, and aorto-iliac in 14 (58%), 3
(13%) and 7 (29%) patients respectively. All of the 24
infected prosthetic grafts replaced were of polyester con-
struction. Clinical symptoms at presentation with infection
are shown in Table 1 and CT findings listed in Table 2. Infec-
tion of the 5 proximal anastomotic aneurysms were related
in 3 patients to graft duodenal fistula through rupture of
a proximal anastomotic aneurysm, and in 2 further patients
to distal anastomotic pseudo aneurysms with frank puru-
lence around the graft.
Aortic reconstruction of the infected graft was
performed as an elective surgical procedure in 18 (75%)
patients with the remaining 6 (25%) performed as emer-
gency procedure due to gastrointestinal bleeding with
shock (nZ 3) or rupture of a proximal anastomotic aneu-
rysm (nZ 3). The mean SD operative time was
320 120 min., ranging between 110 and 480 min, whilst
the mean SD blood transfusion was 3.8 units ranging
from 1 to 11 units.
The peri-operative mortality rate was 21%, 5 of 24
patients. The main causes of death were myocardial
infarction (nZ 2), pulmonary infection (nZ 1), and multi-
ple organ failure (nZ 2). The operative mortality after
emergency aortic reconstruction was 67% versus 6% when
reconstruction was performed as an elective procedure
(P< 0.05).
While the majority 14 (58%) patients had a PGI, 10 (42%)
had a graft infection secondary to a graft sigmoid fistula
(GSF) (nZ 2), aorto-iliac urinary tract fistula (nZ 1) and
graft duodenal fistula (GDF) (nZ 7). Two patients with
GSF presented with signs of peritonitis (Table 1) caused
by erosion of the sigmoid colon by the prosthesis (nZ 1)
and as result of prostatectomy for cancer (nZ 1). Sigmoi-
dectomy with a diverting colostomy and partial graft exci-
sion limited to a single limb was successful for both of
these patients. The patient with an aorto-iliac urinary tract
fistula after cystectomy had an uneventful recovery after
ureteral drainage by a double-J catheter and limb resection
of the infected graft.Table 1 Clinical presentation in 24 patients with an
infected aortic graft
Symptoms N %
Sepsis (fever, leukocytosis, bacteremia) 9 37
Inguinal abscess 8 33
Shock with severe gastrointestinal
bleeding or rupture of false aneurysm
6 25
Abdominal or back pain 6 25
Urinary fistula 1 4
Anorexia and weight loss 2 8
Foot abscess 1 4
Lower limb ischemia 1 4
Peritonitis 2 8Seven patients had GDF comprising duodenal erosion of
the graft (nZ 4) and communication at the level of a prox-
imal aneurysm (nZ 3). Table 3 lists the main features of
these 7 GDF patients. GDFs were treated by gastro-jejunos-
tomy and exclusion of the fistula in one patient, and by
duodenorrhaphy in 5 patients. Segmental duodenal resec-
tion with end-to-end anastomosis was required for the
other patient due to severe damage to the duodenal wall.
Two patients underwent early repeat operation at 7 and
15 days for duodenal leakage after simple primary duodenal
closure. One patient died on Day 50 after gastro-jejunos-
tomy from multi-organ failure whilst the other had an
uneventful recovery after duodeno-jejunostomy. The oper-
ative mortality of patients with GDF was 57% compared
with 6% for those without (p< 0.05). Operative mortality
was 100% in the 3 patients with GDF treated emergently.
Complete graft infection was observed in 19 (79%)
patients with 5 aorto iliac and 14 aorto femoral bypasses.
They all underwent total graft excision and in-situ
replacement with an IGSG. The graft was covered with
a pedicled omentoplasty in 12 (63% of the 19 patients). The
infection was limited to a segment of the graft in 5 (21%)
patients, the body of the graft in 2 patients, and one limb in
3 patients with the remainder of the prosthesis being well
encapsulated in all cases. Each of these 5 patients
underwent in-situ replacement with a segment of IGSG
combined with an omental flap.Symptoms
shock with severe gastro intestinal bleeding 3 (42)
sepsis 2 (29)
abdominal pain 2 (29)
Operative mortality (J30) 4 (57)*
Early reoperation (duodenal leakage) 2 (29)**
Late reoperation (reinfection due to
recurrence of GDF)
1 (14)***
Secondary mortality (> J30) 2 (33)
Bacteriological culture
sterile 4 (57)
polymicrobial 3 (43)
presence of fungus 2 (29)
* 80% of operative mortality.
** 33% of early reoperation.
*** 33% of recurrence of graft infection.
Table 5 Peri-operative complications
Complication N (%)
Partially resolved sciatic and femoral nerve palsy 2 (8)
Iliac venous thrombosis 2 (8)
Femoral anastomotic breakdown 2 (8)
Bacteremia 1 (4)
Acute limb ischemia due to graft occlusion 2 (8)
Prolonged bowel ileus 2 (8)
Duodenal leakage 2 (8)
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(71%). The monomicrobial infections were typically due to
gram-positive species. Table 4 lists the various organisms
cultured. Bacteriological cultures were negative in 8 (33%)
patients. The clinical presentation in these patients was
an inguinal abscess (nZ 3), a urinary fistula (nZ 1),
a GDF with shock (nZ 2) and gastrointestinal bleeding
(nZ 2). CT demonstrated perigraft fluid (nZ 4), perigraft
fluid with an air interface (nZ 3), a retroperitoneal abscess
(nZ 4) and a proximal anastomotic false aneurysm (nZ 3).
Virulent organisms were cultured from 4 (80%) of 5 patients
who died with fungal infection noted in 3 (60%) and Clos-
tridium perfringens in 1 (20%). The fifth culture remained
sterile. Virulent organisms were identified in 9 (47%) of
the 19 surviving patients which was not statistically signifi-
cantly different when compared with those patients who
died (pZ 0.33).
A total of 13 non fatal peri-operative complications
occurred in 11 (46%) patients (Table 5). Early reoperations
were required in 6 (25%) of patients (Table 5). Two patients
underwent early repeat operation for duodenal leakage.
Two other patients presented with femoral anastomotic
breakdown, postoperative day 2 and 6. The aortic graft
infection at the time of replacement was thought to be
limited to the body of the graft and treatment comprised
segmental replacement with IGSG and conservation of the
limb and the femoral anastomosis of the initial prosthesis.
Anastomotic rupture was caused by incomplete resection
of the initial infected prosthesis proven by the fact that
the IGSG was not reinfected. The other two reinterventions
were prompted by acute limb ischemia with 1 patient
undergoing successful femoropopliteal bypass and the
other tibial amputation.
Late secondary procedures were required in 3 patients.
The first patient presented a unilateral femoral false
aneurysm with a periprosthetic collection along the distal
part of one limb after 56 months. Repeat graft limb
replacement with an IGSG segment proved successful after
a follow-up of 14 months. The second patient presentedTable 4 Bacteriological reports for patients with aortic
graft infection
Organism cultured N (% of the total
of the 24 patients)
Gram-positive
Coagulase-negative Staphylococcus 6 (26)
Enterococcus 5 (22)
Methicillin-resistant Staphylococcus
aureus (MRSA)
4 (17)
Streptococcus viridans 4 (17)
Gram-negative
Escherichia coli 3 (13)
Pseudomonas aeruginosa 2 (9)
Klebsiella 2 (9)
Enterobacter 2 (9)
Salmonella 2 (9)
Fungus 5 (21)
Anaerobes 1 (4)with a bilateral femoral false aneurysm. Reinfection of the
entire aortic graft, characterised by a frank purulence
collection along the entire length of the IGSG, was observed
at 60 months. Insertion of a new IGSG has been successful
to date with a follow-up of 13 months. Bacteriologic
analysis of the purulent discharge was negative for both
of these patients. The third patient presented with
a recurrent GDF 15 months after the initial aortic graft
replacement. This was considered a late infection despite
the evidence of IGSG reinfection without peri-prosthetic
collection or peritoneal abscess. This patient was reoper-
ated and died in the postoperative period of myocardial
infarction. Reinfection of the IGSG used for replacement
occurred in 3 (15.7%) of19 surviving patients (Table 6).
Freedom from recurrent infection was 100% and 92.3% at
1 and 3 years respectively (Fig. 1). There were no instances
of late graft occlusion. Primary and secondary patency
rates were 91.7% and 95.8% at 1 and 3 years respectively.
Five (26%) of 19 patients died in the late post-operative
period. Death was due to multiorgan failure (nZ 1),
myocardial infarction (nZ 2) and cancer (nZ 2). Patient
survival rate was 75% at 1 year and 62% at 3 years (Fig. 2).
Discussion
A number of the patients in this study were previously
reported in a multicentre study.10 Long-term follow-up was
complete for the 11 patients of our centre who were in-
cluded in this earlier study. Despite our efforts, it proved
impossible to obtain the late follow-up data for all patients
from the other centres. This problem with multicentre
studies highlights the importance of our single-centre expe-
rience with 24 consecutive patients who were all closely
followed-up. Furthermore, literature is scant on this treat-
ment option for aortic graft infection. Several reasons
explain the paucity of reports. Primarily, aortic graft infec-
tions are fortunately infrequent. Secondly, individual physi-
cians and/or centres have too few cases to publish and do
not all use the same treatment protocol. Finally, no consen-
sus exists on treatment modalities. Our study is unique as
there are no previous reports in the literature which
describes the use of a specific in-situ treatment based on
placement of IGSG.
The primary end-point of this study was the recurrence
of infection. No early recurrent IGSG infection occurred in
our study, but 3 patients (15.7%) developed a late
reinfection diagnosed after 15, 56 and 60 months follow-
up. This highlights the continued risk of recurrence of
infection with the length of follow-up. In this study 3
Table 6 Treatment of aortic graft infections: Results of contemporary studies**
Author (year) n
(follow-up)
Operative
mortality
n (%)
Operative
morbidity
n (%) MLS
Early
occlusion
n (%)
Amputation
n (%)
Reinfection
n (%)
Late
occlusion
n (%)
Dilatation
n (%)
Rupture
n (%)
Late
death
n (%)
Extra-anatomic reconstruction
Seeger et al7
(2000)
36 (32) 4 (11) 15 (42) (NA) 2 (6) 4 (11) 1 (4) 12 (35) 0 1 (4) 3 (12)
1 (4)*
Oderich et al6
(2006)
43 (40) 5 (12) 29 (67)
(21þ/ 17)
NA 4 (9.3) 5 (11.6) 17 (39) 0 4 (9.3) 19 (44)
NA*
In-situ reconstruction
Allografts, Kieffer
et al9 (2004)
179 (46) 36 (20) 36 (20) (NA) 2 (1) 1 (0.5) 1 (0.7) 46 (32) 25 (17) 3 (2) 37 (26)
3 (2)*
Autogenous vein,
Clagett et al4,5
(2005)
242 (56) NA NA NA 0.4 2.4 3.8 0 0.8 NA
Rifampin-bonded
prosthesis,
Oderich et al6
(2006)
52 (40) 4(8) 23 (44) (NA) 3 (6) 0 6 (11.5) 6 (11.5) 0 0 10 (29)
0*
Silver prosthesis,
Current series
24 (32.5) 5 (21) 11 (46)
(23þ/ 19)
2 (8) 1 (4) 3 (15.7) 0 0 0 5 (26)
1 (5)*
* late procedure-related death; NA: not available; MLS: median length of stay.
** our results were compared with other reports on alternative treatment modalities for aortic graft infection, extra-anatomic bypass,
in-situ reconstruction with an autogenous vein, cryopreserved allograft and rifampicin-bonded prosthesis. Appropriate contemporary
single centre studies which were published after 1990 and included more than 20 cases with a mean follow-up of > 24 months were
selected for comparison.
186 M. Batt et al.(15.7%) patients were diagnosed with a graft reinfection
after a mean follow-up of 44 months. An earlier study10
cited only 1 such case (3.7%) of reinfection after a follow-
up of 17 months. Various risk factors for recurrent graft
infection5,17 were present in these 3 patients (GDF, nZ 1;
large perigraft abscess, nZ 0, negative bacteriological cul-
ture, nZ 2; virulent organisms, nZ 2, segmental infected
graft excision, nZ 2; no omentoplasty, nZ 2, factors of
increased susceptibility to infection, nZ 0). Late infection
cannot be linked to infection type or highly virulent
organisms.
Instinct suggests removal of an infected graft in its
entirety rather than a partial excision. However, operative
problems including collateral arteries and salvage, to name
but two, may dictate otherwise according to the macro-
scopic appearance of the graft. Patients (nZ 2) withFreedom from reinfection
0
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0,4
0,5
0,6
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0,8
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Figure 1 Freedom from recurrent infection (Kaplan-Meier
curve).femoral anastomotic breakdown, where there was resec-
tion of the body of the graft, were cultured positive and
polymicrobial with MRSA. The IGSG replacements (nZ 3)
with a single limb were cultured positive in just 1 patient.
However, no secondary interventions were necessary in
these patients.
Questions remain concerning the resistance to infection of
the different grafts used for in-situ reconstruction because
few studies have investigated this point.5,6,8e10,18e20
Autogenous veins and cryopreserved allografts are associ-
ated with the lowest rates of reinfection, 2.4% and 0.7%
respectively (Table 6). This rate of reinfection is compara-
ble with rifampicin-bonded prostheses and IGSG being
11.5% and 15.7% respectively. The antibacterial activity of
the silver or antibiotic-bonded graft over time is probably
the key to limitation of late recurrent infection, but none
of the currently available impregnated prosthetic graftsActuarial survival rate 
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Figure 2 Actuarial survival rate (Kaplan-Meier curve).
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promising (B Braun Silver graft, Aesculap AG, Tuttlingen,
Germany). The silver fibre sealing technology used for this
graft reportedly retains up to 98% of the silver load under
laboratory conditions21 after one year. Publication of clini-
cal studies in human with medium or long-term follow-up is
eagerly awaited to determine the efficacy of this new silver
graft.
In this study, antibiotics were stopped after 6 months
with a late recurrent graft infection of 15.7%. Conversely,
Oderich et al.6 reported a late recurrent graft infection
rate of 11.5% despite life-long oral antibiotic therapy.
Operative morbidity and mortality remained an acceptable
46% and 21% respectively in our overall population and com-
parable with those reported by other authors for patients
treated by extra-anatomic bypass or in-situ reconstruction
with other materials (Table 6).4e7,9,17 These rates appear
attributable more to the patients’ general condition than
to the choice of treatment. In addition, virulent organisms
(46%) and especially fungi cultured in cases of graft duode-
nal fistulas are associated with a tendancy of a higher oper-
ative mortality but it was not statistically significant. Our
study confirms earlier reports5,8,9,17 showing that GDF is
a strong predictor of morbidity and mortality (Table 3).
This was probably related to the fact that 50% of this pa-
tient group underwent an emergency procedure without
preoperative preparation. Special attention must be paid
to the treatment of patients with duodenal fistula, 2 of
whom were re-operated for duodenal leakage which
resulted in 1 death. This is also true for the technique of
pedicled omentoplasty,6 where the recurrence of GDF
resulted in the death of 1 patient where ompentoplasty
was not performed.
Treatment of aortic graft infection is changing. Some
surgeons are in favour of a conservative approach with the
obvious exception of emergency ruptured cases. An
increasing number of authors6,9,10 have broadened the indi-
cations of ISR. Others, however, still reserve staged proce-
dures with initial axillo-bi-femoral reconstruction for
patients with large perigraft abscesses or graft duodenal
fistulas.6,17 A recent meta-analysis18 challenged the status
of extra-anatomic bypass as the gold standard for treat-
ment of aortic graft infection. After pooling the outcome
data for all patients reported in the literature between
January 1985 and August 2005, a statistically significant
difference was evident in favour of patients treated by
ISR with rifampicin-bonded prosthesis, cryopreserved allo-
grafts and autogenous veins compared with those treated
by extra-anatomic bypass. In-situ reconstruction with
a silver graft was not included in this meta-analysis because
only one publication10 was available on this treatment
modality. Calculation of event rates for this single study
on silver did, however, conclude that, under low virulence
conditions, in-situ treatment with silver compared favour-
ably with other in-situ modalities and extra-anatomic
bypass. Silver grafts alone have the added advantage that
they do not contribute to the increasing resistance of anti-
biotics and they had a wide activity profile including meth-
icillin-resistant staphylococcus aureus as is not the case
with rifampicin-bonded prosthesis.22
The various options for in-situ replacement also remain
controversial. Autogenous vein is the most effective methodto avoid recurrent infection4,5,8,18 (Table 6). However, in an
emergency setting which occurred in 25% of cases in our
study, the operative time is an important issue limiting their
applicability. Cryopreserved allografts are associated with
a low rate of recurrent infection9,19 (Table 6) and are less
complicated to use than autogenous veins but can be prob-
lematic for emergent procedures. Graft conditioning in spe-
cialized tissue banks, availability of the correct product
type compounded by limitations for their distribution and
consequently their availability are just a few of the major
factors limiting their utility for elective procedures. More-
over, the rates of late occlusion and late dilation, respec-
tively 32% and 17% raise the question of the durability of
cryopreserved allografts. Conversely, synthetic prostheses
are available in a great variety of types and sizes, are readily
available and offer good late patency rates with acceptable
long term stability. Compared with cryopreserved allo-
grafts, prosthetic grafts rarely lead to late occlusions and
there have been no reports cases of late graft dilation or
graft rupture (Table 6). Nevertheless, questions remain
concerning the resistance to infection of prosthetic grafts,
including IGSG, because few studies have investigated the
issue.6,10,17,20
Conclusion
IGSG appears a reasonable option amongst others for
treatment of the serious problem of graft infection with
a relatively low rate of secondary procedures. However, the
conclusions of our study are limited by the fact that there
was no control group treated with an alternative technique
as well as by the modest mean follow-up of only 32
months. This, however, in the scheme of aortic graft infec-
tions publications is not an insignificant consecutive series
with one single treatment modality over a 6 year period
from a single centre. The greatest advantage of the IGSG
is its ease of use, and availability for emergent procedures
but the risk of reinfection remains of concern as it does
with other modes of treatment.Acknowledgements
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